Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis - Quiz - MDSpire

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

  • By

  • Kerri Miller

  • March 17, 2026

  • 4 min

Share

Original Source(s)

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

  • by Kerri Miller

  • March 17, 2026

Related Content

Editorial: Exploring Cutaneous Drug-Related and Drug-Associated Adverse events: from Clinical Insights to Therapeutic Management

Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice